Project Grant R03CA283252
Award Date
9/12/23
Completion Date
8/31/25
Dollars Obligated
$179K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $107,948 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at The Johns Hopkins University to advance the development of a liquid biopsy screening test for early detection of ovarian cancer. The key objectives are to: 1) expand bioinformatics approaches to study repeat elements in cell-free DNA, 2) develop sensitive and specific cell-free DNA liquid biopsies for ovarian cancer, and 3) characterize genomic changes to repeat...
This $411,876 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support research to explore the use of PIWI-interacting RNAs (piRNAs) as novel biomarkers for the early detection of ovarian cancer. The University of Arkansas for Medical Sciences (UAMS) will perform piRNA sequencing analysis to identify overexpressed piRNA candidates in early-stage ovarian tumor tissues and sera from early-stage ovarian cancer patients,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research by Rutgers University to investigate how dysfunctions in the cellular response to mitochondrial stress influence the progression of epithelial ovarian cancer and the orchestration of protective anti-tumor immunity. The $936,746 award, running from December 1, 2024 to November 30, 2029, will leverage the university's unique mouse models, reagents, and extensive ovarian...
The National Cancer Institute (NCI) awarded a 5-year, $637,371 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Northwestern University. The grant aims to develop a microfluidic platform for the rapid, non-invasive isolation and expansion of circulating tumor-reactive lymphocytes (CTRLs) from the blood of ovarian cancer patients. This innovative technology has the potential to enable a new class of effective, second-line immunotherapies against...
This Project Grant award of $419,133 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of the "AscitesPredictTM" technology at the Massachusetts Institute of Technology (MIT). The project aims to create an "ex vivo tumor biosensor" that can evaluate cell identities and therapeutic sensitivities from patient ascites fluid samples obtained during routine medical care. The technology utilizes...
The National Cancer Institute (NCI) awarded a $554,653 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Institute for Systems Biology in Seattle, Washington. The grant, titled "RARECYTEFINDER: A BENCH-TO-BITS TOOLKIT FOR LABEL-FREE, WHOLE-SPECTRUM ANALYSIS OF RARE DISSEMINATED TUMOR CELLS IN LIQUID AND TISSUE BIOPSIES", seeks to develop an innovative, unbiased method for identifying and analyzing rare disseminated tumor cells (DTCs) in liquid and tissue...
This federal Project Grant award of $390,290 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to study the role and regulation of modified microRNAs (miRNAs) in cancer. The primary awardee, The Ohio State University, will use the funding to:
Analyze the function and post-transcriptional regulation of the broader miRNA landscape in a cancer context through in-silico analyses and experimental validations.
Develop ISOMIRGATE, a freely...
This $275,000 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project objectives are to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ machine learning to...
This federal Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $703,540 to Brigham & Women's Hospital to develop and optimize implantable microdevices for predicting patient response to cancer treatments. The key objectives are:
Validate the performance of the implantable microdevice technology to predict clinical response to immunotherapy and chemotherapy in head and neck cancer patients. This data will...
This federal Project Grant award for $415,830, awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring and detection of reliable biomarkers that represent treatment response and drug resistance in ovarian cancer.
The award will fund the development of the Nano-CRISPR system, which incorporates single extracellular vesicle (EV)...